186 related articles for article (PubMed ID: 23828516)
1. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.
Di Matteo P; Hackl C; Jedeszko C; Valentinis B; Bordignon C; Traversari C; Kerbel RS; Rizzardi GP
Br J Cancer; 2013 Jul; 109(2):360-9. PubMed ID: 23828516
[TBL] [Abstract][Full Text] [Related]
2. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V; Citterio G; Vitali G; Spreafico A; Scifo P; Borri A; Donadoni G; Rossoni G; Corti A; Caligaris-Cappio F; Del Maschio A; Esposito A; De Cobelli F; Dell'Acqua F; Troysi A; Bruzzi P; Lambiase A; Bordignon C
Eur J Cancer; 2010 Jan; 46(1):198-206. PubMed ID: 19900802
[TBL] [Abstract][Full Text] [Related]
3. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
[TBL] [Abstract][Full Text] [Related]
4. The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.
Porcellini S; Asperti C; Valentinis B; Tiziano E; Mangia P; Bordignon C; Rizzardi GP; Traversari C
Oncoimmunology; 2015 Oct; 4(10):e1041700. PubMed ID: 26451306
[TBL] [Abstract][Full Text] [Related]
5. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
6. Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF.
Di Matteo P; Mangia P; Tiziano E; Valentinis B; Porcellini S; Doglioni C; Sanvito F; Bordignon C; Rizzardi GP; Traversari C
Clin Exp Metastasis; 2015 Mar; 32(3):289-300. PubMed ID: 25648442
[TBL] [Abstract][Full Text] [Related]
7. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
8. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors.
Liang PH; Tian F; Lu Y; Duan B; Stolz DB; Li LY
Angiogenesis; 2011 Mar; 14(1):61-8. PubMed ID: 21188501
[TBL] [Abstract][Full Text] [Related]
10. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
Corti A; Curnis F; Rossoni G; Marcucci F; Gregorc V
BioDrugs; 2013 Dec; 27(6):591-603. PubMed ID: 23743670
[TBL] [Abstract][Full Text] [Related]
11. Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling.
Liu G; Chen Y; Qi F; Jia L; Lu XA; He T; Fu Y; Li L; Luo Y
J Pathol; 2015 Oct; 237(2):190-202. PubMed ID: 25988668
[TBL] [Abstract][Full Text] [Related]
12. Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance.
Roodhart JM; He H; Daenen LG; Monvoisin A; Barber CL; van Amersfoort M; Hofmann JJ; Radtke F; Lane TF; Voest EE; Iruela-Arispe ML
Blood; 2013 Jul; 122(1):143-53. PubMed ID: 23690447
[TBL] [Abstract][Full Text] [Related]
13. Breaking the 'harmony' of TNF-α signaling for cancer treatment.
Sasi SP; Yan X; Enderling H; Park D; Gilbert HY; Curry C; Coleman C; Hlatky L; Qin G; Kishore R; Goukassian DA
Oncogene; 2012 Sep; 31(37):4117-27. PubMed ID: 22158049
[TBL] [Abstract][Full Text] [Related]
14. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Shaked Y; Henke E; Roodhart JM; Mancuso P; Langenberg MH; Colleoni M; Daenen LG; Man S; Xu P; Emmenegger U; Tang T; Zhu Z; Witte L; Strieter RM; Bertolini F; Voest EE; Benezra R; Kerbel RS
Cancer Cell; 2008 Sep; 14(3):263-73. PubMed ID: 18772115
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models.
Okazaki T; Ebihara S; Asada M; Kanda A; Sasaki H; Yamaya M
Int Immunol; 2006 Jan; 18(1):1-9. PubMed ID: 16352631
[TBL] [Abstract][Full Text] [Related]
16. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V; Santoro A; Bennicelli E; Punt CJ; Citterio G; Timmer-Bonte JN; Caligaris Cappio F; Lambiase A; Bordignon C; van Herpen CM
Br J Cancer; 2009 Jul; 101(2):219-24. PubMed ID: 19568235
[TBL] [Abstract][Full Text] [Related]
18. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis.
Dondossola E; Rangel R; Guzman-Rojas L; Barbu EM; Hosoya H; St John LS; Molldrem JJ; Corti A; Sidman RL; Arap W; Pasqualini R
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20717-22. PubMed ID: 24297924
[TBL] [Abstract][Full Text] [Related]
19. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies.
Taylor M; Rössler J; Geoerger B; Laplanche A; Hartmann O; Vassal G; Farace F
Clin Cancer Res; 2009 Jul; 15(14):4561-71. PubMed ID: 19605404
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor increases tumor growth and angiogenesis directly by promoting endothelial cell function and indirectly by enhancing the mobilization and recruitment of proangiogenic granulocytes.
Zheng Q; Li X; Cheng X; Cui T; Zhuo Y; Ma W; Zhao X; Zhao P; Liu X; Feng W
Tumour Biol; 2017 Feb; 39(2):1010428317692232. PubMed ID: 28240048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
